Turning over renal osteodystrophy dogma: direct actions of FGF23 on osteoblast β-catenin pathway.
Although recognized as a major complication of chronic kidney disease (CKD), the pathophysiology of the CKD-related mineral and bone disorder (CKD-MBD) is not completely understood. Recently, the inhibition of Wnt/β-catenin pathway in osteocytes by sclerostin has been shown to play a role in CKD-MBD. The study by Carrilo-Lopez et al. confirms this inhibition in an experimental model of CKD. Moreover, they describe direct actions of FGF23-Klotho on osteoblasts, increasing the expression of DKK1, another Wnt/β-catenin pathway inhibitor.
PreciThera, Montreal, Quebec, Canada.
Susan C
SC
Schiavi
Medicine Master Degree Program, Universidade Nove de Julho, Universidade Nove de Julho, São Paulo, Brazil; Nephrology Division, Universidade de São Paulo, São Paulo, Brazil. Electronic address: rosa.moyses@uol.com.br.
Rosa M A
RM
Moysés
D001847:Bone Diseases; D012080:Chronic Kidney Disease-Mineral and Bone Disorder; D000089703:Fibroblast Growth Factor-23; D006801:Humans; D010006:Osteoblasts; D060449:Wnt Signaling Pathway; D051176:beta Catenin
C000717427:FGF23 protein, human; D051176:beta Catenin; D000089703:Fibroblast Growth Factor-23